Cognitive preservation advantage and efficacy balance of magnetic seizure therapy in adolescent Major Depressive Disorder: a randomized controlled trial revealing efficacy cognition decoupling phenomenon.
{"title":"Cognitive preservation advantage and efficacy balance of magnetic seizure therapy in adolescent Major Depressive Disorder: a randomized controlled trial revealing efficacy cognition decoupling phenomenon.","authors":"Wei Wang, Yi Lu, Guo-Lin Mi, Xiao-Jing Li, Dan-Ning Zhang, Su-Fang Qi","doi":"10.1708/4583.45901","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To compare magnetic seizure therapy (MST) and modified electroconvulsive therapy (MECT) in adolescent major depressive disorder (MDD) regarding cognitive protection (assessed via the Montreal Cognitive Assessment, MoCA) and suicidality improvement (assessed via the Columbia-Suicide Severity Rating Scale, C-SSRS), with a focus on cognitive subdomains and the mediating role of cognitive changes.</p><p><strong>Methods: </strong>This analysis stems from a prospective, assessor-blinded randomized controlled trial (RCT, ChiCTR2500098032) conducted from March 1 to April 30, 2025, at Shandong Mental Health Center, enrolling 120 adolescents aged 13-18 with MDD, randomized 1:1 to MST (n=60) or MECT (n=60). Primary outcome was the Beck Depression Inventory-II (BDI-II) percentage reduction; secondary outcomes included MoCA subdomain scores, C-SSRS suicidality, and adverse events (CTCAE 5.0). Correlation, mediation (Sobel test), and repeated-measures ANOVA (RM-ANOVA) assessed the cognitive-suicidality relationship. Assessments occurred at baseline and 7 days post-treatment.</p><p><strong>Results: </strong>MECT yielded a higher BDI-II reduction rate, with no significant difference in response rate. MST significantly improved MoCA total score, particularly in memory, orientation, and executive function subdomains. MST enhanced suicidality outcomes, with a higher remission rate. The correlation between MoCA change and suicidality improvement was stronger in MST, with mediation analysis indicating a partial mediating role of MoCA improvement in MST. MST showed fewer adverse events and shorter reorientation time.</p><p><strong>Conclusions: </strong>In adolescent MDD, MST offers efficacy comparable to MECT for depression relief, with superior cognitive protection (especially memory, orientation, and executive function) and safety. The association between cognitive improvement and suicidality reduction suggests MST may indirectly mitigate suicide risk via cognitive preservation, providing a novel treatment option. Multicenter, long-term studies are needed to confirm these findings.</p>","PeriodicalId":21506,"journal":{"name":"Rivista di psichiatria","volume":"60 5","pages":"196-201"},"PeriodicalIF":1.3000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Rivista di psichiatria","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1708/4583.45901","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: To compare magnetic seizure therapy (MST) and modified electroconvulsive therapy (MECT) in adolescent major depressive disorder (MDD) regarding cognitive protection (assessed via the Montreal Cognitive Assessment, MoCA) and suicidality improvement (assessed via the Columbia-Suicide Severity Rating Scale, C-SSRS), with a focus on cognitive subdomains and the mediating role of cognitive changes.
Methods: This analysis stems from a prospective, assessor-blinded randomized controlled trial (RCT, ChiCTR2500098032) conducted from March 1 to April 30, 2025, at Shandong Mental Health Center, enrolling 120 adolescents aged 13-18 with MDD, randomized 1:1 to MST (n=60) or MECT (n=60). Primary outcome was the Beck Depression Inventory-II (BDI-II) percentage reduction; secondary outcomes included MoCA subdomain scores, C-SSRS suicidality, and adverse events (CTCAE 5.0). Correlation, mediation (Sobel test), and repeated-measures ANOVA (RM-ANOVA) assessed the cognitive-suicidality relationship. Assessments occurred at baseline and 7 days post-treatment.
Results: MECT yielded a higher BDI-II reduction rate, with no significant difference in response rate. MST significantly improved MoCA total score, particularly in memory, orientation, and executive function subdomains. MST enhanced suicidality outcomes, with a higher remission rate. The correlation between MoCA change and suicidality improvement was stronger in MST, with mediation analysis indicating a partial mediating role of MoCA improvement in MST. MST showed fewer adverse events and shorter reorientation time.
Conclusions: In adolescent MDD, MST offers efficacy comparable to MECT for depression relief, with superior cognitive protection (especially memory, orientation, and executive function) and safety. The association between cognitive improvement and suicidality reduction suggests MST may indirectly mitigate suicide risk via cognitive preservation, providing a novel treatment option. Multicenter, long-term studies are needed to confirm these findings.
目的:比较磁惊厥治疗(MST)和改良电惊厥治疗(MECT)在青少年重度抑郁症(MDD)的认知保护(通过蒙特利尔认知评估,MoCA评估)和自杀改善(通过哥伦比亚自杀严重程度评定量表,C-SSRS评估)方面的差异,重点研究认知子域和认知变化的中介作用。方法:本分析来源于一项前瞻性、评估盲随机对照试验(RCT, ChiCTR2500098032),于2025年3月1日至4月30日在山东省精神卫生中心进行,纳入120名13-18岁的MDD青少年,按1:1的比例随机分为MST组(n=60)或MECT组(n=60)。主要终点为贝克抑郁量表- ii (BDI-II)百分比下降;次要结局包括MoCA子域评分、C-SSRS自杀倾向和不良事件(CTCAE 5.0)。相关性、中介(Sobel检验)和重复测量方差分析(RM-ANOVA)评估了认知与自杀的关系。评估在基线和治疗后7天进行。结果:MECT组BDI-II降低率较高,两组有效率无显著差异。MST显著提高了MoCA总分,特别是在记忆、定向和执行功能子域。MST提高了自杀结局,缓解率更高。在MST中,MoCA变化与自杀改善的相关性更强,中介分析表明MoCA改善在MST中起部分中介作用。MST的不良反应较少,重新定位时间较短。结论:在青少年MDD患者中,MST在抑郁缓解方面的疗效与MECT相当,具有更好的认知保护(尤其是记忆、定向和执行功能)和安全性。认知改善和自杀率降低之间的关系表明MST可能通过认知保护间接降低自杀风险,提供了一种新的治疗选择。需要多中心的长期研究来证实这些发现。
期刊介绍:
Gli interessi della rivista riguardano l’approfondimento delle interazioni tra mente e malattia, la validazione e la discussione dei nuovi strumenti e parametri di classificazione diagnostica, la verifica delle prospettive terapeutiche farmacologiche e non.